Nabriva appoints Dr Elyse Seltzer as Chief Medical Officer
Posted: 22 May 2015 |
Nabriva has announced the appointment of Elyse Seltzer, MD, as Chief Medical Officer. Dr Seltzer assumes the role from Dr William Prince…
Nabriva has announced the appointment of Elyse Seltzer, MD, as Chief Medical Officer.
Dr Seltzer assumes the role from Dr William Prince, who will transition to Senior Vice President, Clinical Science.
Based in Philadelphia, Dr Seltzer will supervise medical and regulatory aspects of clinical development and medical affairs for Nabriva and contribute to the company’s clinical development strategy. She will work closely with Dr Steven Gelone, the recently appointed Chief Development Officer at Nabriva, as well as the clinical operations team, to execute Nabriva’s clinical development programme, including the planned Phase 3 clinical trials of lefamulin for the treatment of community-acquired bacterial pneumonia (CABP). Dr Prince will be responsible for the Phase 1 and scientific programmes required to support the lefamulin development programme for CABP and additional indications.
Dr Seltzer will assist in advancing Nabriva’s lead comment, lefamulin
Dr Colin Broom, Chief Executive Officer of Nabriva, commented on the appointment, “We are very pleased to welcome Elyse to Nabriva. Her extensive experience in the anti-infective therapeutic area, and in leading international clinical development programmes will enable us to efficiently advance our lead product, lefamulin, into late stage development for the treatment of CABP. We have established a world class clinical development leadership team to advance our pipeline with a sense of urgency to address an area of significant medical need.”
Elyse Seltzer, newly appointed Chief Medical Officer of Nabriva, added, “I am thrilled to join Nabriva. I am excited to have the opportunity to advance a novel class of antibacterials, particularly given the current and evolving challenges around resistance to currently available antibiotics. I look forward to working with the highly experienced clinical team to fulfil this goal.”
Dr Seltzer has a strong track record in clinical development within the pharmaceutical industry. She joins Nabriva from GlaxoSmithKline (GSK), where she was Vice President of Global Clinical Sciences and Operations. Prior to joining GSK, Dr Seltzer was Chief Medical Officer at Tengion, a regenerative medicine company. She has also held roles at Centocor and Vicuron, where she led the dalbavancin clinical development programme. Dr Seltzer began her industry career in Anti-Infectives Clinical Research and Development at SmithKline Beecham (now GSK). Before joining the pharmaceutical industry, she practiced clinical Infectious Diseases medicine.
Dr Seltzer holds an MD in Medicine from the New York University School of Medicine. She completed her Internal Medicine training at the University of Pennsylvania Medical Centre, and her Infectious Diseases training at Yale New Haven Hospital.
